Pliant Therapeutics, Inc. (PLRX) Investor Relations Documents

Pliant Therapeutics, Inc. (PLRX) investor relations documents from the company's IR site: 1 presentation, 32 press releases; latest deck 2026-06-18. Read in-app with summaries. First-party data.

June 2026 Pliant Corporate Presentation: Pliant Therapeutics' PLN-101095, an oral αVβ8/αVβ1 inhibitor, demonstrated anti-tumor activity with 4/10 responders in ICI-refractory solid tumors, with a median response duration

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-18Press releasePliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatme
2026-08-11Press releasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-07-13Press releasePliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
2026-06-18PresentationJune 2026 Pliant Corporate Presentation
2026-05-21Press releasePliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-11Press releasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-06Press releasePliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2026-04-30Press releasePliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101
2026-04-18Press releasePliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Ref
2026-03-18Press releasePliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumor
2026-03-11Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
2026-02-23Press releasePliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
2025-12-04Press releasePliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advan
2025-03-03Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
2024-11-07Press releasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
2024-08-07Press releasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
2024-05-06Press releasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-02-27Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
2023-11-09Press releasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-08-09Press releasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-05-09Press releasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-03-09Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
2022-11-08Press releasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-08-08Press releasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-05-09Press releasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
2021-11-09Press releasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021-08-09Press releasePliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-05-10Press releasePliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
2021-04-05Press releasePliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference
2021-03-16Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
2020-11-10Press releasePliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
2020-08-11Press releasePliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results
Press releasePliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

PLRX overview · PLRX earnings · PLRX financials · PLRX KPIs · PLRX ownership · PLRX peers · PLRX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.